Thermo Fisher Scientific Human CD273 (B7-DC) Synthetic Peptide

Applications

Control (Ctrl)

• Assay-dependent

Blocking Assay (BLOCK)

• Assay-dependent

Product Specifications

Product Specific Information

This peptide corresponds to 16 amino acids near the center of human PDL-2.
PEP-0464 can be used as a blocking peptide with polyclonal antibody PA5-20344.

Target Information

Programmed death-ligand 2 (PD-L2), also known as B7-DC, is a member of the B7 ligand family within the immunoglobulin superfamily. Along with PD-L1, it acts as a ligand for programmed death protein 1 (PD-1).
PD-L2 is primarily expressed in dendritic cells but can be induced in various immune and non-immune cells depending on the microenvironment. Its expression is upregulated by Th2 cytokine IL-4 and to a lesser extent by Th1 cytokines TNF-alpha and IFN-gamma.
Although expressed at lower levels than PD-L1, PD-L2 binds PD-1 with 2–6 times higher affinity. PD-1 and its ligands function as inhibitory immune checkpoint molecules that regulate immune homeostasis by inhibiting T cell activation, proliferation, and cytokine secretion (e.g., IFN-gamma, IL-10).
Interestingly, PD-L2 can also stimulate T cell proliferation and cytokine production even in PD-1-deficient T cells, suggesting additional receptors. Recent studies identified repulsive guidance molecule b (RGMb) as another PD-L2 receptor, originally known as a receptor for bone morphogenetic proteins (BMPs). RGMb is expressed in the central nervous system and macrophages, with emerging roles in immunity.
The PD-L2–RGMb interaction regulates respiratory tolerance development in the lung through BMP and/or neogenin signaling pathways. The human PD-L2 monomer consists of a 201-amino-acid extracellular domain, a 21-amino-acid transmembrane domain, and a 32-amino-acid cytoplasmic domain.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.